Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 14/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.46 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9544995 | 1.00 | MCL1 (0.51) | MCL1USP30UCHL1HTRA1P2RX3 | |
| SCHEMBL192535 | 1.00 | MCL1 (0.51) | MCL1USP30UCHL1HTRA1P2RX3 | |
| SCHEMBL29015574 | 1.00 | MCL1 (0.51) | MCL1USP30UCHL1HTRA1P2RX3 | |
| SCHEMBL6842708 | 1.00 | MCL1 (0.51) | MCL1USP30UCHL1HTRA1P2RX3 | |
| SCHEMBL192536 | 1.00 | MCL1 (0.51) | MCL1USP30UCHL1HTRA1P2RX3 | |
| SCHEMBL23452261 | 1.00 | MCL1 (0.51) | MCL1USP30UCHL1HTRA1P2RX3 | |
| SCHEMBL7462140 | 0.90 | MCL1 (0.53) | MCL1P2RX3 | |
| SCHEMBL27190373 | 0.90 | MCL1 (0.53) | MCL1P2RX3 | |
| SCHEMBL27190288 | 0.90 | MCL1 (0.53) | MCL1P2RX3 | |
| SCHEMBL7722150 | 0.90 | MCL1 (0.50) | MCL1UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-3110810-B1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9920075-B2 | Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-6770741-B1 | USEFUL IN TREATING CONDITIONS AND DISEASES OF A MAMMAL AND HUMAN IN WHICH AN EXCESS OF BRADYKININ OR RELATED KININS ARE PRODUCED OR INJECTED SUCH AS BY INSECT BITES | SCIOS INC. | 2004-08-03 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1189612-A1 | VLA-4 INHIBITOR COMPOUNDS | Daiichi Pharmaceutical Co., Ltd. (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-0618810-B1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2001000206-A1 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-04 | — | — | WO | disclosed |
| US-5385889-A | Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist | SCIOS NOVA INC. (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1992018156-A1 | BRADYKININ ANTAGONIST PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | MCL1 1889/4885USP30 4492/4885UCHL1 4606/4885 |
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | MCL1 340/4885USP30 4522/4885UCHL1 3675/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | MCL1 1889/4885USP30 4492/4885UCHL1 4606/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | MCL1 1529/4885USP30 2603/4885UCHL1 1669/4885 |
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | MCL1 1983/4885USP30 4692/4885UCHL1 4141/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | MCL1 1889/4885USP30 4492/4885UCHL1 4606/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | MCL1 1529/4885USP30 2603/4885UCHL1 1669/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | MCL1 1889/4885USP30 4492/4885UCHL1 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.